https://oncodaily.com Oncology News, Cancer Research & Clinical Insights Sat, 18 Apr 2026 18:50:36 +0000 en-US 10 Oncodaily.com https://oncodaily.com/pub/themes/oncodailynews/img/logo-ODN-round.png https://oncodaily.com https://oncodaily.com/pub/uploads/2025/10/OD-favicon-blank-320x320.webp https://oncodaily.com 32 32 https://oncodaily.com/techology/crossbridge-bio486815 Sat, 18 Apr 2026 18:50:36 +0000 02ddbdc1ba3ee3556a2f3d3e7e8fa0f7

Eli Lilly Acquires CrossBridge Bio for ~$300M, Securing a Next-Generation ADC Platform to Accelerate Oncology Expansion Eli Lilly and Company has announced the acquisition of CrossBridge Bio for approximately $300 […]]]> https://oncodaily.com/voices/jean-jacques-kiladjian-486909 Sat, 18 Apr 2026 18:37:30 +0000 3d72583609ad9d1ad9c0e4e2d5ae4b5d

Jean-Jacques Kiladjian, Professor of Medicine, Head of Clinical Research Department of Inserm (National Institute of Health and Medical Research), shared a post on LinkedIn: “Honored to be invited by the […]]]> https://oncodaily.com/techology/bnt323486811 Sat, 18 Apr 2026 18:23:54 +0000 1fd39c8241721c56c68b5a2f729774a7

BioNTech’s BNT323 Delivers Compelling Phase 2 Efficacy in HER2-Expressing Endometrial Cancer, BLA Submission Targeted for 2026 BioNTech has reported Phase 2 clinical data for trastuzumab pamirtecan (BNT323), its HER2-targeting antibody-drug […]]]> https://oncodaily.com/voices/advocacy-summit-486893 Sat, 18 Apr 2026 18:16:55 +0000 3cc39321c00ac3339785ad6b60ece65e

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: “Calling all cancer care advocates! The 2026 ASCO Advocacy Summit Week of Action starts on Monday. We’re calling on […]]]> https://oncodaily.com/techology/asgard-therapeutics486876 Sat, 18 Apr 2026 18:08:21 +0000 d4e5353de618b58dd7a981236c808cad

Asgard Therapeutics Presents First-in-Class Preclinical Data for AT-108, an In Situ Gene Therapy That Reprograms Tumor Cells Into Dendritic Cells Asgard Therapeutics has disclosed preclinical data for AT-108, a first-in-class […]]]> https://oncodaily.com/voices/vilma-pacheco-barcia-486878 Sat, 18 Apr 2026 17:56:49 +0000 3f6b4ef14e3789f79de9d1b1ad390792

Vilma Pacheco Barcia, Head of the Medical Oncology Department at Hospital Universitario La Luz, Gastrointestinal Cancer Unit at One Oncology Madrid Program, Quirónsalud, shared a post on LinkedIn: “Very grateful for the […]]]> https://oncodaily.com/techology/merck486797 Sat, 18 Apr 2026 17:49:42 +0000 287004615f06b2b7d145ef314a895058

Merck has disclosed initial first-in-human clinical data for MK-2010, a bispecific antibody designed to simultaneously block the PD-1 and VEGF pathways, in a presentation at the American Association for Cancer […]]]> https://oncodaily.com/career/leon-bernal-mizrachi486865 Sat, 18 Apr 2026 17:42:24 +0000 7e626288d3306ecc2577791b27cf7ed4

Leon Bernal-Mizrachi, Chair of Cancer Medicine for Wake Forest University School of Medicine, shared a post on LinkedIn: “It’s an honor to be part of American Society of Clinical Oncology. I’m grateful […]]]> https://oncodaily.com/voices/yannick-romero-486861 Sat, 18 Apr 2026 17:25:56 +0000 f628862a84564c6e86868c76942d3a44

Yannick Romero, Senior Knowledge and Advocacy Manager at Union for International Cancer Control (UICC), shared an article on LinkedIn: “Thank you, Benjamin Plackett and Nature journal for highlighting the work […]]]> https://oncodaily.com/oncolibrary/lung-oncology/zongertinib-her Sat, 18 Apr 2026 17:15:48 +0000 7e9218aac9aad6e0a140ac66f24a7bac

For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]]]>